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Discrimination of Prion Strain
Targeting in the Central Nervous
System via Reactive Astrocyte
Heterogeneity in CD44 Expression
Barry M. Bradford* , Christianus A. W. Wijaya and Neil A. Mabbott*
The Roslin Institute and R(D)SVS, The University of Edinburgh, Edinburgh, United Kingdom
Prion diseases or transmissible spongiform encephalopathies are fatal, progressive,
neurodegenerative, protein-misfolding disorders. Prion diseases may arise
spontaneously, be inherited genetically or be acquired by infection and affect a
variety of mammalian species including humans. Prion infections in the central nervous
system (CNS) cause extensive neuropathology, including abnormal accumulations of
misfolded host prion protein, vacuolar change resulting in sponge-like (spongiform)
appearance of CNS tissue, neurodegeneration and reactive glial responses. Many
different prion agent strains exist and these can differ based on disease duration,
clinical signs and the targeting and distribution of the neuropathology in distinct brain
areas. Reactive astrocytes are a prominent feature in the prion disease affected CNS
as revealed by distinct morphological changes and upregulation of glial fibrillary acidic
protein (GFAP). The CD44 antigen is a transmembrane glycoprotein involved in cell-cell
interactions, cell adhesion and migration. Here we show that CD44 is also highly
expressed in a subset of reactive astrocytes in regions of the CNS targeted by prions.
Astrocyte heterogeneity revealed by differential CD44 upregulation occurs coincident
with the earliest neuropathological changes during the pre-clinical phase of disease, and
is not affected by the route of infection. The expression and distribution of CD44 was
compared in brains from a large collection of 15 distinct prion agent strains transmitted
to mice of different prion protein (Prnp) genotype backgrounds. Our data show that the
pattern of CD44 upregulation observed in the hippocampus in each prion agent strain
and host Prnp genotype combination was unique. Many mouse-adapted prion strains
and hosts have previously been characterized based on the pattern of the distribution
of the spongiform pathology or the misfolded PrP deposition within the brain. Our data
show that CD44 expression also provides a reliable discriminatory marker of prion
infection with a greater dynamic range than misfolded prion protein deposition, aiding
strain identification. Together, our data reveal CD44 as a novel marker to detect reactive
astrocyte heterogeneity during CNS prion disease and for enhanced identification of
distinct prion agent strains.
Keywords: prion, transmissible spongiform encephalopathy, neurodegeneration, neuroinflammation, astrocyte,
CD44
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INTRODUCTION
Prion diseases, or transmissible spongiform encephalopathies,
are a unique group of infectious, sub-acute, neurodegenerative
disorders. These disease have been identified in several
mammalian species and include scrapie in sheep and goats,
bovine spongiform encephalopathy (BSE) in cattle, chronic
wasting disease (CWD) in cervids and Creutzfeldt-Jakob
disease (CJD) in humans. During prion disease, abnormally
folded isoforms (PrPSc) of the host-encoded cellular prion
protein (PrPC) accumulate and aggregate in affected tissues
(Prusiner, 1982). The infectious prion is considered to constitute
almost entirely of PrPSc implying that prions are infectious
proteins. Prion disease within the central nervous system
(CNS) causes extensive neuropathology and neurodegeneration.
This characteristically includes neuronal vacuolation resulting
in a spongiform (sponge-like) appearance of brain tissue in
histopathological specimens (Fraser and Dickinson, 1967) and
progressive loss of dendritic spines (Fang et al., 2016), synapses
(Jeffrey et al., 2000), axons (Jeffrey et al., 1995) and neuronal
cell bodies (Giese et al., 1995). These histopathological signs are
also accompanied by activation of the astrocytes and microglia
(Kercher et al., 2007).
Many distinct prion agent strains have been identified
and characterized by transmission into laboratory mice (Boyle
et al., 2017). Once adapted to their new host environment,
these prion strains can be stably maintained by passage
within that same host species, resulting in reproducible
disease incubation periods, clinical presentation and targeting
of prion neuropathology (Dickinson and Fraser, 1977). As
well as conservation of biological properties, prion strains
also have preserved biochemical properties, which has led to
the hypothesis that the distinct conformational state of the
misfolded prion protein encodes this diversity (Safar et al., 1998;
Peretz et al., 2001, 2002; Arima et al., 2005). The diversity
in the targeting of neuropathological changes within the CNS
resulting from different prion strains has been key to facilitating
strain identification (Fraser and Dickinson, 1967, 1968, 1973;
Bruce et al., 1989, 1991; Fraser, 1993; van Keulen et al., 2015;
Boyle et al., 2017).
Reactive astrocytes are a prominent feature in the prion
disease affected brain but whether they play a role in the
development of, or protection from, the neurodegeneration
during prion disease is uncertain. Both neurons and astrocytes
can facilitate prion agent replication (Diedrich et al., 1991; Race
et al., 1995; Raeber et al., 1997; Kovács et al., 2005; Sarasa et al.,
2012; Krejciova et al., 2017) and induce microglial recruitment
(Marella and Chabry, 2004) at early stages of prion disease
neuropathogenesis. Indeed expression of the prion protein
gene (Prnp) in astrocytes alone is sufficient to support prion
infection in the brains of infected mice (Raeber et al., 1997).
Data from an in vitro study have suggested that the reactive
astrocytes may also play a role in the recruitment of microglia
toward regions of the brain affected by prions (Marella and
Chabry, 2004). To-date, analyses of the astrocytic response
during prion infection have predominantly focused on the
immunohistochemical detection of upregulated expression of the
intermediate filament glial fibrillary acidic protein (GFAP) and
morphological changes to the astrocyte cytoskeleton (Georgsson
et al., 1993; Monzon et al., 2018). However, independent studies
have shown that the activation status of the reactive astrocytes
is highly heterogeneous (Zamanian et al., 2012), and can be
broadly categorized into neurotoxic ‘A1’ or neuroprotective
‘A2’ phenotypes based on functional and transcriptional
characteristics (Liddelow et al., 2017). Whether CNS prion
infections also lead to the development of neurotoxic or
neuroprotective phenotypes in astrocytes, and whether this
differs amongst different prion agent strains is not known.
Transcriptional analyses have shown that expression of
the adhesion molecule CD44 is significantly elevated in
reactive astrocytes induced by a range of pro-inflammatory
stimuli (Liddelow et al., 2017). Furthermore, the expression
of CD44 expression was significantly elevated in neurotoxic
A1 astrocytes when compared to the A2 astrocytes with a
neuroprotective phenotype. Therefore, in the current study we
used the immunohistochemical analysis of CD44 expression to
characterize the heterogeneity of the reactive astrocyte response
in the brains of mice infected with a large range of distinct prion
agent strains. We show that in the brains of mice infected with
prions, strong astrocyte-associated CD44 expression was detected
as early as halfway through the disease incubation period and
concurrent with some of the earliest neuropathological changes.
Data from prion disease transmission to mice have revealed
the discriminatory properties and limitations of disease-specific
vacuolation or PrPd in identifying prion disease strain and host
differences. Furthermore, not all prion diseases are transmissible
to laboratory mice, and for novel natural prion disease cases the
incubation period of disease is often unknown. The identification
of a novel marker of prion disease that can discriminate prion
strains in different host Prnp genotypes irrespective of survival
time or route of infection could prove useful in understanding the
variety of strains in natural prion disease cases both in humans
and animals. Our data from the analysis of a large collection
brains from mice infected with 15 distinct prion agent strains
suggest CD44 expression fulfils these criteria and can be used as
a novel marker to detect reactive astrocyte heterogeneity during
CNS prion disease.
MATERIALS AND METHODS
Animals
C57BL/Dk and VM/Dk mice were bred and housed under
specific pathogen-free conditions with a 12:12 h light:dark cycle.
Food and water were provided ad libitum. Necessary approvals
for the mouse experiments described in this study were obtained
from the Institute for Animal Health Neuropathogenesis Unit
Ethical Review Committee, the University of Edinburgh Ethical
Review Committee, and the UK Home Office.
Prion Infection
Groups of C57BL/Dk, VM/Dk and F1 cross offspring termed
“CVF1” mice were injected intracerebrally (IC) with 20 µl of
a 1% (weight/volume) brain homogenate prepared from mice
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terminally infected with prions. For intraperitoneal (IP) or
intravenous (IV) infection the mice were injected with the same
dose and volume of prions into the peritoneal cavity or tail vein,
respectively. For oral infection mice were individually housed
overnight in bedding-free cages with a single food pellet dosed
with 50 µl of a 1% (weight/volume) brain homogenate. The
mice were maintained in these cages until the food pellet was
fully consumed, upon which they were then returned to standard
group caging. All mice were coded and assessed by independent
technicians at weekly intervals for the clinical signs of prion
disease. Mice were scored as “unaffected,” “possibly affected”
and “definitely affected” using standard criteria (Brown et al.,
2012) and culled at a standard clinical end-point (maximally
on their 3rd clinical assessment of definitely affected). Mean
disease survival times were calculated as the interval between
infection with prions and the detection of positive clinical signs
of terminal prion disease.
Neuropathological Analysis
Clinical prion disease diagnoses were confirmed by
histopathological assessment of vacuolation (spongiform
pathology) in the brain. Brains were codified at post-mortem
and fixed in 10% formal saline, trimmed into 5 routine coronal
slices based on external features, processed and embedded
in paraffin wax. Sections were cut at 6 µm thickness, stained
with hematoxylin & eosin and scored for spongiform vacuolar
degeneration by blinded assessment as described previously
(Fraser and Dickinson, 1967). Sections were scored by an
independent scientist for the presence and severity (scale 0–5)
of prion-disease-specific vacuolation in nine gray matter and
three white matter brain areas: G1, dorsal medulla; G2, cerebellar
cortex; G3, superior colliculus; G4, hypothalamus; G5, medial
thalamus; G6, hippocampus; G7, septum; G8, cerebral cortex;
G9, forebrain cerebral cortex; W1, cerebellar white matter; W2,
midbrain white matter; W3, cerebral peduncle.
Immunohistochemistry (IHC)
Sections (6 µm) were cut on a HM325 Rotary Microtome
(Thermo Fisher Scientific, Runcorn, United Kingdom) and
mounted on Superfrost Plus slides (Menzel-Glaser GmbH,
Braunschweig, Germany). Before immunostaining the sections
were deparaffinised using an XL Autostainer (Leica Biosystems,
Newcastle upon Tyne, United Kingdom) and pre-treated by
autoclaving (15 min at 121◦C) in Target Retrieval Solution pH
6.0 (DAKO UK Ltd., Ely, United Kingdom). For the detection
of PrP sections were then immersed in formic acid (98%)
for 5 min, and subsequently immunostained with anti-PrP-
specific mAb [Clone BH1] (Morales et al., 2007). To detect
astrocytes the sections were immunostained with rabbit anti-
GFAP (DAKO), biotinylated anti-mouse/human CD44 [Clone:
IM7] (Biolegend, London, United Kingdom) or anti CD44var6
[Clone 9A4] (eBioscience, Ltd., Hatfield, United Kingdom).
To detect microglia the sections were immunostained with
anti-Iba1 polyclonal antibody (AIF1; Wako Chemicals GmbH,
Neuss, Germany). Following the addition of primary antibodies,
biotin-conjugated species-specific secondary antibodies (Jackson
ImmunoResearch Europe Ltd., Ely, United Kingdom) were
applied. Biotinylated antibidies were detected using horse radish
peroxidase-conjugated to the avidin-biotin complex [HRP-ABC]
kit (Vector Laboratories, Peterborough, United Kingdom) and
visualized with 3,3’-diaminobenzidine [DAB] (Merck KGaA,
Darmstadt, Germany) and counterstained with hematoxylin. For
dual CD44/GFAP staining, CD44 was detected using the HRP
substrate Vector NovaRed (Vector Laboratories, Peterborough,
United Kingdom) and GFAP detected with alkaline phosphatase
conjugated anti-rabbit antibody (Jackson Immunoresearch) and
5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium
(BCIP/NBT) substrate (Merck). Sections were viewed using
an Eclipse Ni-E microscope (Nikon Instruments Europe BV,
Amsterdam, Netherlands) with Zen software (Carl Zeiss Ltd.
Cambridge, United Kingdom).
Immunofluorescence
For immunofluorescence analysis, goat anti-rabbit iFluora594
(AAT Bioquest, Sunnyvale, United States) was applied
following anti-GFAP immunostaining, and goat anti-mouse
Alexaflluor647TM (Life Technologies Ltd., Inchinnan,
United Kingdom) was applied following anti-PrP (clone BH1)
immunostaining. For CD44 and CD44v6 staining procedures
were performed as above and visualized using the HRP substrate
Tyramide iFluora488 (AAT Bioquest). Sections were mounted
using fluorescent mounting medium (DAKO) before analysis.
Images were captured using a confocal laser scanning LSM710
microscope with Zen software (Zeiss).
Thioflavin Staining of Amyloid
Paraffin-embedded sections as above were dewaxed and
rehydrated, incubated in 1% thioflavin-S (Merck KGaA) for
5 min, differentiated in 70% industrial denatured alcohol for
3 × 1 min and washed in distilled water. Slides were mounted
using fluorescent mounting medium (DAKO) and images
captured using a confocal laser scanning LSM710 microscope
with Zen software (Zeiss).
Image Analysis
For morphometric analysis, coded IHC sections and images
were analyzed using ImageJ software1 by blinded assessment
as described (Inman et al., 2005). Images were captured from
a minimum of N = 6 mice/group. To visualize staining
intensity the deconvoluted DAB channel was false-colored
using an inverted 16 color lookup table [LUT] representing
variance in pixel intensity (see calibration bar in each figure).
Thus, each image was color deconvoluted using the vector
H-DAB and the percentage area coverage of each IHC marker
in each of the 9 gray matter areas was then measured.
Data are expressed as mean ± SEM from a minimum of
72 images/profile.
Statistical Analysis
Survival periods, vacuolation scores and percentage area
coverage of IHC staining are presented as mean ± SEM from
N = 4–31 mice/group. Pearson correlation coefficients were
1http://rsb.info.nih.gov/ij/
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calculated from N = 6 mice/group. Survival time and image
analysis quantification data were compared using paired T-tests.
Statistical analyses were performed using Minitab 17 software
(Minitab Ltd., Coventry, United Kingdom).
RESULTS
Comparison of Survival Times and
Neuropathology in a Large Collection of
Distinct Mouse-Adapted Prion Agent
Strains
The identification or definition of distinct prion strains from
various sources has been well characterized by their transmission
into laboratory mice (Boyle et al., 2017). These analyses show that
distinct prion agent strains can differ significantly in the duration
of the survival times and the targeting of the neuropathology
(spongiform pathology) in the brain. Therefore, in the current
study we compiled a large collection of brains from mice infected
with 15 distinct and defined mouse-adapted strains and used it
to compare glial cell responses during CNS prion disease. Full
details of all the prion agent strains used and the recipient mouse
strain backgrounds are provided in Table 1.
Prion agent strain characteristics can also be significantly
influenced by host Prnp genotype (Dickinson and Meikle, 1971).
Therefore, in this study we studied brains from C57Bl/Dk mice
that have the Prnp-a (108L, 189T) genotype, and VM/Dk mice
that have a Prnp-b (108F, 189V) genotype (Westaway et al., 1987).
All mice were injected IC with a 1% dose of brain homogenate
and brains were analyzed at the terminal stage of disease. The
relative prion disease survival times in the recipient mice are
shown in Figure 1. These data show that the order of the
relative survival times, particularly in CVF1 mice, can be used to
distinguish similar strains such as 79A from 139A for example.
The distribution and magnitude of the prion disease-specific
spongiform pathology (vacuolation) in nine gray matter regions
and three white matter regions of the brains from mice in each
group are shown in Figure 2. These data, in combination with
the survival time data in Figure 1 have enabled each of these
distinct strains to be identified and distinguished from each other
in the brains of laboratory mice (Bruce et al., 1997). These data
were used here to confirm the nature and identity of these distinct
prion agent strains used for the further investigations below.
PrPSc Deposition
The abnormal accumulation of misfolded prion disease-specific
PrP (PrPd) is a characteristic feature in the brain during
CNS prion disease. The pattern of the PrPd deposition within
the brains of infected mice has previously been used to help
discriminate some prion agent strains, although this was not
possible for all strains analyzed (van Keulen et al., 2015). Here,
to compare the pattern of PrPd deposition between distinct prion
agent strains, terminal brain sections were immunostained using
anti-PrP antibody BH1. The resulting images were then false-
colored to compare the signal intensities of the immunostaining
between strains (Figure 3). In the brains of C57Bl/Dk mice most
prion strains could be distinguished by PrPd deposition pattern
as shown previously (van Keulen et al., 2015). However, the
dynamic range was low due to the diffuse and widespread nature
of the PrPd deposition observed for some prion agent strains
including 22A, 22C, 22F, 79A, 80A, and 139A (Figures 3C,E).
Variance was also minimal between the hippocampal CA2-
focussed 87A (Figure 3B) and 79V (Figure 3E) strains, and the
intense PrP deposits observed throughout the hippocampus of
mice infected with the ME7 (Figure 3B) and 22L prion agent
strains (Figure 3C). However, the PrP deposition observed in
the brains of mice infected with BSE (Figure 3D) and CWD
(Figure 3F) derived prion strains was readily distinguishable
from those of scrapie origin (Figures 3B,C,E).
TABLE 1 | Prion agent strains analyzed in this study.
Strain Disease Origin Passage Passage/line References
ME7 Natural sheep scrapie Suffolk sheep 9th C57Bl/Dk Zlotnik and Rennie, 1963
22A Experimental sheep scrapie SSBP1 Cheviot sheep 10th VM/Dk Dickinson and Meikle, 1969
22C Experimental sheep scrapie SSBP1 Cheviot Sheep 8th C57Bl/Dk Dickinson, 1976
22F Experimental sheep scrapie SSBP1 Cheviot Sheep 9th C57Bl/Dk Dickinson, 1976
22L Experimental sheep scrapie SSBP1 Cheviot Sheep 13th C57Bl/Dk Dickinson, 1976
79A Experimental sheep scrapie SSBP1 ‘Drowsy’ goat 12th C57Bl/Dk Dickinson, 1976; Pattison and Millson, 1961
79V Experimental sheep scrapie SSBP1 ‘Drowsy’ goat 5th VM/Dk Dickinson, 1976; Pattison and Millson, 1961
80A Experimental sheep scrapie SSBP1 ‘Scratching’ goat 5th C57Bl/Dk Pattison and Millson, 1961
87A Natural sheep scrapie Cheviot × Border Leicester sheep 9th C57Bl/Dk Bruce et al., 1976
87V Natural sheep scrapie Cheviot x Border Leicester sheep 9th VM/Dk Bruce et al., 1976
139A Experimental sheep scrapie SSBP1 ‘Drowsy’ goat Chandler isolate 9th C57Bl/Dk Chandler, 1961; Pattison and Millson, 1961
221C Natural sheep scrapie Halfbreed sheep 4th C57Bl/Dk Bruce et al., 2002
301C BSE Holstein-Fresian cow 7th C57Bl/Dk Bruce et al., 1994
301V BSE Holstein-Fresian cow 7th VM/Dk Bruce et al., 1994
409V CWD Mule deer 5th VM/Dk Bruce et al., 2002∗
∗Confirmed US CWD case material identified circa 1980 provided by Stuart Young and Beth Williams, Wild Animal Disease Center and Department of Pathology, College
of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United States (Williams and Young, 1980).
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FIGURE 1 | Mean prion disease survival times in laboratory mice infected with
a variety of distinct prion agent strains. Groups of C57Bl/Dk (Prnp-a), CVF1
(Prnp-a/b) or VM/Dk (Prnp-b) mice were injected intracerebrally with a variety
of distinct prion agent strains (Table 1) and survival times recorded from mice
confirmed to have clinical and pathological signs of prion disease. Mean
survival times in days ± SEM are displayed for each mouse-passaged prion
strain group (N = 4–31 mice/group, total = 446 mice). Attempted
transmissions of the 87 V strain to C57Bl/Dk or CVF1 mice have not
produced positive clinical or pathological signs of prion disease in recipient
mice up to at least 600 days post injection.
Next, the percentage area coverage of PrPd+ immunostaining
was measured across nine distinct brain gray matter areas
(Figure 4). The intensity of the PrPd+ immunostaining across
these areas was then compared between each prion agent
strain by paired T-test (Supplementary Table 1). This analysis
showed the highly discriminatory nature of PrPd detection in
prion agent strain typing and revealed statistically significant
differences in 55% (84/153) of comparisons. For example 22A-
C57Bl/Dk was almost completely distinguishable by PrPd profile
against all other strains, except when compared against 80A-
C57Bl/Dk (P = 0.052, Supplementary Table 1). Similarly the
PrPd profiles for BSE (301C & 301V) and CWD (409V) derived
prion agent strains were readily discriminated from most natural
and experimental scrapie strains with high levels of significance.
However as noted above, this analysis showed that several
strains were indistinguishable across many brain regions due to
similarities in the amount of PrPd present, as reported previously
(van Keulen et al., 2015).
In addition to data from the analysis of a range of natural
sheep scrapie, experimental sheep scrapie, experimental goat
scrapie and BSE, derived agent strains, we also present data from
the serial passage of CWD prions (derived from Mule Deer)
in VM/Dk mice (prion agent strain 409V). Staining with
thioflavin-S showed that amyloid PrPd accumulations were a
characteristic feature in the brain after infection with 409V prions
(Figure 5A). In terminally affected VM mice these florid amyloid
PrP plaques were mostly observed in the corpus callosum dorsal
to the hippocampus and occasionally in the thalamus. In the
brains of C57Bl/Dk mice large florid and multicentric plaques
were observed in the corpus callosum and throughout the
thalamus and hippocampus (Figure 5A). Comparison of the
pattern of the PrPd accumulation across all the prion agent
strains used in this study suggested that the features of the
amyloid accumulations could be reliably used to distinguish the
CWD-derived 409V prion agent strain following experimental
transmission to mice (Figures 3F, 5A).
Glial Activation
Microglia are the phagocytic cells of the brain and their
activation during CNS prion disease is also a prominent
histopathological characteristic (Aguzzi and Zhu, 2017).
Microglia are critical in host defence against prion disease and
appear to phagocytose prions and delay disease pathogenesis
(Carroll et al., 2018). Microglia proliferate and infiltrate prion-
affected brain areas and display activated morphology as
identified by immunostaining for allograft inflammatory factor 1
(AIF1; Figure 5B, upper row).
Next, the percentage area coverage of AIF1+ immunostaining
was measured across nine distinct brain gray matter areas
(Figure 6). As above, the intensity of the AIF1+ immunostaining
across these areas was then compared between each prion agent
strain by paired T-test (Supplementary Table 2). This analysis
showed the discriminatory extent of AIF1+ immunostaining
in prion agent strain discrimination in the brain revealing
statistically significant differences in 48% (73/153) of
comparisons (Supplementary Table 2). Of note, prion agent
strains with the highest levels (e.g., 22C-C57Bl/Dk and 87A-
C57/Dk) and lowest levels (e.g., 409V-C57Bl/Dk) of AIF1+
immunostaining generated some of the highest statistically
significant differences when compared to most other strains.
Astrocytes contribute to the maintenance of health and
function of the CNS and are considered important in
neurodegenerative diseases (Phatnani and Maniatis, 2015)
including prion disease (Aguzzi and Liu, 2017). Reactive
astrocytes were identified by immunostaining for the
intermediate filament GFAP and their altered morphology
(Figure 5B, lower row). The precise role and function of
astrocytes in prion disease is not known beyond regional
variance in their activation dependent upon prion strain
(Monzon et al., 2018) and ability to replicate prions (Sarasa et al.,
2012; Krejciova et al., 2017), hence their selection for further
investigation in this study.
Next, the percentage area coverage of GFAP+ immuno-
staining was measured across nine distinct brain gray matter
areas (Figure 6). The intensity of the GFAP+ immunostaining
across these areas was then compared between each prion
agent strain by paired T-test (Supplementary Table 3). This
analysis suggested that GFAP+ immunostaining had the
least discriminatory properties revealing statistically significant
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FIGURE 2 | Comparison of the magnitude and distribution of the spongiform pathology in the brains of mice infected with a variety of distinct prion agent strains.
Groups of C57Bl/Dk or VM/Dk mice were injected intracerebrally with a variety of distinct prion agent strains (Table 1). Brains were collected at the terminal stage of
disease and the magnitude and distribution of the spongiform pathology (vacuolation) scored for each of the following brain regions G1, dorsal medulla; G2,
cerebellar cortex; G3, superior colliculus; G4, hypothalamus; G5, medial thalamus; G6, hippocampus; G7, septum; G8, cerebral cortex; G9, forebrain cerebral
cortex; W1, cerebellar white matter; W2, midbrain white matter; W3, cerebral peduncle. Data represent mean vacuolation severity scores ± SEM.
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FIGURE 3 | Immunohistopathological comparison of the PrPd immunostaining in the brains of mice infected with a variety of distinct prion agent strains. Groups of
C57Bl/Dk or VM/Dk mice were injected intracerebrally with a variety of distinct prion agent strains (Table 1). Brains were collected at the terminal stage of disease
and immunostained to detect PrPd. Images were then false-colored to compare the signal intensities of the immunostaining between each group. (A) Normal brain
infected mice display no PrPd compared to mice terminally affected with ME7 scrapie prions. (B–F) Comparison of false colored images to show the variation in
PrPd+ immunostaining between diverse prion strains isolated from a variety of sources. Representative images from 6 mice/group are shown. Scale bars = 500 µm.
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FIGURE 4 | (A–E) Comparison of the magnitude and distribution of the PrPd+ immunostaining in the brains of mice infected with a variety of distinct prion agent
strains. Groups of C57Bl/Dk or VM/Dk mice were injected intracerebrally with a variety of distinct prion agent strains (Table 1). Brains were collected at the terminal
stage of disease and immunostained to detect PrPd and the percentage area coverage compared in each of the following gray matter brain regions G1, dorsal
medulla; G2, cerebellar cortex; G3, superior colliculus; G4, hypothalamus; G5, medial thalamus; G6, hippocampus; G7, septum; G8, cerebral cortex; G9, forebrain
cerebral cortex. N = 6 mice/group. Data represent mean ± SEM, from a minimum of 54 images/group.
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FIGURE 5 | Histopathological detection of amyloid and activated glial cells in
the brain following prion infection. (A) Thioflavin-S staining of normal brain
C57Bl/Dk, 87V-VM/Dk, 409V-C57Bl/Dk and 409V-VM/Dk prion agent strain
and host combinations revealed characteristic amyloid deposits in the brains
of mice with amyloidal PrP accumulations. Images are representative of N = 4
mice/group. Scale bars = 100 µm. (B) Immunohistochemical detection of
microglia (AIF1+ cells, upper row) and astrocytes (GFAP+ cells, lower row).
This analysis showed minimal AIF1+ and GFAP+ immunostaining in the
brains of uninfected control mice, whereas expression of these markers was
strongly upregulated in brains of mice with terminal prion disease.
Representative images N = 6 mice/group are shown. Scale bars = 500 µm.
differences in only 34% (52/153) of prion agent strain
comparisons. Of note, prion agent strains with low levels of
GFAP+ immunostaining (e.g., CWD-derived 409V-C57Bl/Dk
and 409V-VM/Dk) or large regional diversity (e.g., 22L-
C57Bl/Dk and to a lesser extent 22F-C57Bl/Dk and 87V-VM/Dk)
generated some of the highest statistically significant differences
when compared to most other strains.
CD44 Expression Is Upregulated During
CNS Prion Disease
Molecular profiling of reactive astrocytes has identified CD44 as
a pan-activation marker (Liddelow et al., 2017). In the brains of
mice with terminal ME7 prion disease CD44 immunostaining
was observed in a wide range of areas and sub-regions
(Figure 7A). Furthermore, immunostaining for CD44 and GFAP
suggested that CD44 was associated with astrocytes (Figure 7B).
Next, mice were injected IC with ME7 scrapie prions and
the expression of CD44 in the brain compared throughout
the pre-clinical phase. At 45 day post-injection (dpi) with
prions, upregulated CD44 expression was only detected in
association with the damage caused by the injection needle-track
(Figure 7C, upper row). However, by 80 dpi CD44 expression
was elevated in the thalamus on the same side of the brain
as the injection site. This coincided with early signs of PrPd
accumulation, and evidence of astrocyte and microglia activation
(Figure 7C, middle row). By 118 dpi CD44 upregulation was
also observed in the contralateral thalamus and mirrored the
distribution of the astrocyte activation (Figure 7C, bottom
row). When Cd44 mRNA is expressed alternative splicing can
encode different CD44 isoforms. For example, CD44 variant
6 isoform (CD44v6) containing exon 11 is upregulated by
and interacts with the chemotactic and phagocytosis inducing
microglial expressed protein osteopontin (Weber et al., 1996;
Katagiri et al., 1999; Gao et al., 2003; Marroquin et al., 2004; Khan
et al., 2005; Morisaki et al., 2016). Our data suggest that the CD44
expressed during these early pre-clinical stages appeared to be
predominantly of the CD44v6 isoform (Figure 7C).
We next determined whether the route of prion exposure
influenced the expression of CD44 in the brain. Our analysis
showed a similar upregulation of CD44 expression in the
brain at the terminal stage of disease after exposure to prions
via intraperitoneal injection, IV injection or oral infection
(Figure 7D). These data show that for the ME7 prion agent strain
the specified pattern of CD44 upregulation in the CNS during
prion disease is unaffected by the route of infection.
Distinct Patterns of CD44 Expression in
the Brains of Mice Infected With
Different Prion Agent Strains
Little if any CD44 expression was detected by IHC in the
brains of uninfected control mice, whereas abundant CD44
expression was detected in the brains of C57Bl/Dk mice infected
with ME7 scrapie prions (Figure 8A). We next compared the
distribution and abundance of CD44 expression in the brains
of mice infected with distinct prion agent strains. To specifically
compare the abundance and variance of the CD44 upregulation
between prion agent strains, immunostained images were false-
colored in respect to pixel intensity. This analysis revealed
patterns of CD44 upregulation in the brain that were specific
for each prion agent strain (Figures 8B–E). Furthermore, by
comparing the CD44 expression profile specifically within the
hippocampus, it was possible to discriminate each prion agent
strain/host combination based solely on CD44 localization
(Table 2 and Figure 8). CD44 heterogeneity within activated
astrocytes has been previously identified in mouse models of
Alexander disease (Sosunov et al., 2013). Our data suggest that
CD44 upregulation within the hippocampus is also a useful
marker to discriminate the neuropathological changes during
CNS prion disease.
This analysis also revealed that the abundance of the CD44
expression in the brains of mice with terminal prion disease
appeared to mirror the magnitude and distribution of the PrPd.
For example, in prion agent strain/recipient mouse genotype
combinations that displayed diffuse PrPd accumulation e.g.,
ME7, experimental sheep scrapie 22A, 22C, 22F, and 22L and
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FIGURE 6 | (A–E) Comparison of the magnitude and distribution of the GFAP+ and AIF1+ immunostaining in the brains of mice infected with a variety of distinct
prion agent strains. Groups of C57Bl/Dk or VM/Dk mice were injected intracerebrally with a variety of distinct prion agent strains (Table 1). Brains were collected at
the terminal stage of disease and immunostained to detect GFAP+ cells (astrocytes) and AIF1+ cells (microglia). The percentage area coverage of each marker was
then compared in each of the following gray matter brain regions G1, dorsal medulla; G2, cerebellar cortex; G3, superior colliculus; G4, hypothalamus; G5, medial
thalamus; G6, hippocampus; G7, septum; G8, cerebral cortex; G9, forebrain cerebral cortex. N = 6 mice/group. Data represent mean ± SE, from a minimum of 54
images/group.
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FIGURE 7 | CD44 expression is upregulation in the brain during prion disease. (A) C57Bl/Dk mice were injected intracerebrally with ME7 scrapie prions and brains
collected at the terminal stage of disease and immunostained to detect CD44. Scale bar = 1,000 µm. (B) Dual immunostaining for CD44 and GFAP suggested a
correlation in their patterns implying an astrocyte origin. Scale bar = 100 µm. (C) C57Bl/Dk mice were injected intracerebrally with ME7 scrapie prions, brains were
collected at intervals after infection and immunostained to detect CD44, CD44v6, GFAP and IBA1. Analysis of brains from 45, 80, and 118 days post injection (dpi)
shows the progressive increase in expression from the needle-track, injection side thalamus and bilateral spread, respectively. Images are representative of N = 4
mice/group. Scale bars = 2,000, 100, or 200 µm as indicated. Upregulation of CD44 coincided with astrocyte (GFAP) and microglial (AIF1) responses. (D) CD44
pattern in terminal mouse brain following intracerebral, intraperitoneal, intravenous or oral ME7 infection reveals similar distribution of immunostaining irrespective of
the route of exposure. Survival times (days) indicated. Images representative of N = 6 mice/group. Scale bars = 500 µm.
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FIGURE 8 | Distinct patterns of CD44+ immunostaining in the hippocampus region of the brains of mice infected with a variety of distinct prion agent strains.
Groups of C57Bl/Dk or VM/Dk mice were injected intracerebrally with a variety of distinct prion agent strains (Table 1). Brains were collected at the terminal stage of
disease and immunostained to detect CD44. Images were then false-colored to compare the signal intensities of the immunostaining between each group.
(A) Normal brain infected mice display little CD44+ immunostaining when compared to mice terminally affected with ME7 scrapie prions. (B–F) Comparison of false
colored images to show the variation in CD44+ immunostaining between diverse prion strains isolated from a variety of sources. Representative images from 6
mice/group are shown. Scale bars = 500 µm.
experimental goat scrapie derived strains 79A, 79V, 80A and
139A, the abundance of the CD44 expression was similarly diffuse
(Figures 3B,C,E, 8B,C,E). However, in mice infected with 409V
prions, the CD44 expression almost exclusively associated with
regions containing amyloid PrPd accumulations.
Since host Prnp genotype can significantly affect prion disease
survival times and the characteristics of the neuropathology
(Dickinson and Fraser, 1977; van Keulen et al., 2015), we next
compared CD44 expression in the brains of C57Bl/Dk mice
or VM/Dk mice infected with the ME7 or 22A scrapie prion
agent strains. This analysis showed infection of C57Bl/Dk mice
or VM/Dk mice with the same prion agent strain gave rise
to distinct patterns of CD44 expression in the hippocampus
(Figures 8B,C). This analysis suggests that host Prnp genotype
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TABLE 2 | Prion agent strain typing based on hippocampal CD44 expression pattern.
Strain-Host CA1 CA2 CA3 DG
ME7-C57/Dk +++ so +++ sr + slm + so + sr +++ so + sp ++ slu +++ sr ++ po ++ superior mo +++ inferior mo
22A-C57/Dk +++ so∗ +++ sr∗ +++ slm∗ – +++ sr∗ +++ superior mo∗ ++ inferior mo∗
22C-C57/Dk + so + so ++ sr∗ ++ so∗ ++ superior mo∗ +++ inferior mo∗
22F-C57/Dk +++ so∗ ++ sp +++ sr∗ +++ slm∗ ++ so∗ ++ sp ++ sr∗ ++ so∗ ++ sr∗ ++ superior mo + inferior mo ∗mo apex
4 22L-C57/Dk + so∗ ++ sr∗ + so∗ + sr∗ ++ so∗ + slu + sr + superior mo ++ inferior mo
79A-C57/Dk + so + sr + so + sr ++ so ++ slu + mo ‘astrocytic’
79V-C57/Dk – + so + sr +++so ++ slu + sr + slm + inferior mo
80A-C57/Dk – + so +slu +++ so +++ inferior mo
87A-C57/Dk + so + sr + so +++ sr + slu ++ inferior mo∗
139A-C57/Dk ++ so ++ sr + so + sr +++ so ++ slu +++ inferior mo
221C-C57/Dk – – ++ so + slu + ‘astrocytic’/inferior mo
409V-C57/Dk – – – + peri plaque DG/Thalamus
301C-C57/Dk + so∗ + so∗ + sr ++ slm∗ + slu –
301V-C57/Dk + slm – + slu +++ mo ‘astrocytic’
ME7-VM/Dk ++ so∗ ++ sp ++ sr∗ ++ slm ++ so ++ sr ++ slm +++ so∗ +++ sr∗ + slm + mo ‘astrocytic’ + po
22A-VM/Dk +++ so∗ ++ sp +++ sr∗ +++ slm∗ ++ so∗ ++ sr∗ +++ slm∗ ++ so∗ +++ sr∗ +++ slm ++ mo∗ ++ po∗
87V-VM/Dk + so + sr ++ slm + so + sr + so ++ slu ++ apex mo
409V-VM/Dk + peri plaque so/cc – – –
∗Regions also stain positive for CD44v6. cc, corpus callosum; mo, molecular layer; po, polymorph layer; slm, stratum lacunosum moleculare; slu, stratum lucidum; so,
stratum oriens; sp, stratum pyrimidale; sr, stratum radiatum.
may also influences the expression pattern of CD44 in the CNS
during prion disease.
Next, the magnitude of the CD44+ immunostaining was
compared for each strain/host combination investigated by
calculating the mean percentage area coverage across nine
distinct gray matter areas (Figures 9A–E). The intensity of
the CD44+ immunostaining across these areas was then
compared between each prion agent strain by paired T-test
(Supplementary Table 4). This analysis highlighted the
discriminatory nature of reactive astrocyte heterogeneity
in CD44 in the brains of mice infected with distinct prion
agent strains. Furthermore, this analysis suggested that
CD44+ immunostaining had the most discriminatory properties
revealing statistically significant differences in 70% (107/153) of
comparisons. Of note BSE (301C and 301V) and CWD (409V)
derived strains and ME7-C57Bl/Dk were highly statistically
significantly different from other scrapie derived strains.
Furthermore the same prion strain, e.g., ME7 or 22A produced
statistically significantly different profiles when in different
Prnp genotype hosts.
Representative images of AIF1+; CD44+, CD44v6+, GFAP+
and PrPd+ immunostaining on serial sections from brains
from all the prion agent strain/recipient mouse combinations
studied are provided in Supplementary Figure 1. Analysis of the
correlation of these neuropathological markers of CNS prions
disease (AIF1+microglia; CD44+ and GFAP+ astrocytes; PrPd)
showed the variance across all the prion agent strain/recipient
mouse combinations studied (Supplementary Table 5). This
analysis suggested that the strongest and most significant
correlate was CD44 with GFAP amongst most strain-host
combinations. Also of note was the lack of correlation
with AIF1+ microglia when comparing the neuropathology
of ME7 prion agent strain in the brains of C57Bl/Dk
mice and VM/Dk mice.
CD44 Upregulation Is Astrocytic and
Correlates With Prion Accumulation
In the brains of mice infected with several prion agent
strains, astrocytic patterns of PrPd deposition can be detected
(Figure 10A). Our analysis suggested that the regions of the brain
with astrocytic prion accumulation mirrored those displaying
high levels of CD44. Immunostaining with the N-terminal pan-
CD44 antibody showed diffuse neuropil staining with un- or
lightly stained astrocytes in relief (Figure 10B). Co-staining
with the pan-CD44 antibody and GFAP similarly showed
minimal direct co-localisation between these two proteins in
astrocytes (Figure 10C). This observation is consistent with
the demonstration that the pan-CD44 antibody recognizes an
N-terminal epitope in the cleavable and soluble ectodomain of
the CD44 protein (Nagano and Saya, 2004).
Activation of CD44v6 isoform on endothelial cells requires
association of the CD44 carboxy-terminus with ezrin that couples
the CD44v6 isoform to the cytoskeleton (Tremmel et al., 2009).
At the terminal stage prion disease our IHC analysis showed
that the CD44v6 isoform displayed either an intense staining
pattern throughout the astrocyte, or mixed pattern including
strong staining throughout the astrocyte and a surrounding
diffuse staining pattern (Figure 10D). The pattern of CD44v6
immunostaining appeared to be more distinctly localized when
compared to the widespread and diffuse pattern obtained
with pan-CD44 staining. It is plausible that the pan-CD44
upregulation observed at the terminal stage also includes
standard CD44 and/or splice variants other than CD44v6.
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FIGURE 9 | (A–E) Comparison of the magnitude and distribution of the CD44+ immunostaining in the brains of mice infected with a variety of distinct prion agent
strains. Groups of C57Bl/Dk or VM/Dk mice were injected intracerebrally with a variety of distinct prion agent strains (Table 1). Brains were collected at the terminal
stage of disease and immunostained to detect CD44. The percentage area coverage of CD44+ immunostaining was then compared in each of the following gray
matter brain regions G1, dorsal medulla; G2, cerebellar cortex; G3, superior colliculus; G4, hypothalamus; G5, medial thalamus; G6, hippocampus; G7, septum; G8,
cerebral cortex; G9, forebrain cerebral cortex. N = 6 mice/group. Data represent mean ± SEM, from a minimum of 54 images/group.
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FIGURE 10 | CD44v6 expression and PrPd colocalize with GFAP + astrocytes in the brains during prion disease. (A) Immunohistochemical demonstration of
astrocytic PrPd immunostaining patterns in brains of mice infected with certain prion agent strains. (B,C) Immunohistochemical analysis shows pan-CD44
expression surrounds but does not co-localize with GFAP in astrocytes. (D) Immunostaining for CD44v6 shows astrocytic staining pattern suggesting that astrocytes
are the predominant cellular source of CD44 upregulation during prion disease. A–C scale bars = 100 µm. (E) Immunofluorescent analysis of CD44, GFAP and PrPd
in the brains of mice with prion disease shows that CD44+ /GFAP+ astrocytes accumulate PrPd. Scale bars = 20 µm.
For example, in the brains of human Alzheimer’s disease
patients upregulation of splice variants CD44v3 and CD44v10
as well as CD44v6 has also been observed (Pinner et al., 2017).
This combination of staining patterns also suggests that
CD44v6 may have undergone extracellular cleavage and
binding to the cytoskeleton in specific astrocyte subpopulations
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(Figures 10D,E). IHC for GFAP, CD44v6 and PrPd revealed
colocalization in specific astrocyte populations (Figure 10E).
DISCUSSION
Prion diseases are a diverse group of infectious
neurodegenerative disorders that are considered to be caused
by abnormally folded prion protein. The observation of
different clinical syndromes following the transmission of
experimental scrapie prions in goats led to the suggestion
of variation in prion strains (Pattison and Millson, 1961).
Transmissions into laboratory mice proved that prion disease
isolates may be resolved into individual strains of infectious
agent, that retain specific properties including the duration
of the survival time and the targeting of the neuropathology
to defined brain areas (Bruce, 2003). Of course, one of the
major contentious issues in the prion hypothesis is how a
misfolded host protein (PrPSc) can encode such diverse strain-
specific properties. Plausibly, the prion agent diversity may be
encoded partly or in combination through variation in primary
structure, N-linked glycosylation and folding confirmation
(Morales et al., 2007). The exact mechanisms that control prion
agent strain targeting within the CNS are unknown, despite
the neuroinflammatory nature of prion neurodegeneration
being identified (Burwinkel et al., 2004; Riemer et al., 2009;
Crespo et al., 2012).
In this study, we set out to characterize astrocyte responses
to prion infection and uncovered a host response to infection
that defines prion strain targeting within the CNS. Until
now prion strain typing has typically involved lengthy and
expensive transmission experiments in panels of laboratory
mice (Boyle et al., 2017). However, this detailed prion strain-
typing is necessary for the identification and characterization
of novel and emerging prion diseases, especially those with
zoonotic potential. Here we show that prion agent strains
can be readily discriminated via profiling of astrocyte CD44
expression within the CNS. In the current study, astrocyte
responses to prion infection were characterized using anti-pan-
CD44 and the splice variant specific anti-CD44v6 antibodies on
a wide-range of mouse-adapted prion disease strains derived
from sheep scrapie, BSE and CWD. We show that the
upregulation of CD44 expression occurs in sub-region specific
brain areas revealing an undiscovered level of heterogeneity in
astrocyte populations following prion infection. Further analysis
showed that the variety in the presentation of the CD44+
immunostaining between each prion stain/host combination
revealed unique and distinguishable patterns, especially within
the hippocampus. Indeed even in the brains of mice infected
with the amyloidogenic mouse-adapted CWD strain 409V,
the astrocytes surrounding the PrP plaques responded via
upregulating both GFAP and CD44. Furthermore, the expression
profile of the CD44+ immunostaining in mice infected with
the ME7 scrapie agent strain was unaltered by the route of
infection. CD44 was upregulated as early as halfway through
the incubation period and occurred concurrently with some of
the earliest neuropathological changes. CD44 positive astrocytes
also displayed accumulation of PrPSc, suggesting they may act as
reservoirs for prion production within the CNS during infection.
Following on from our analysis of prion agent strain-specific
CD44 patterns in brains of experimentally infected mice, further
work is now required to investigate the variation in CD44
expression patterns in natural prion disease in both human and
animal hosts. Such analysis is essential to determine whether
this the pattern of the CD44+ immunostaining in the brain can
similarly be used to discriminate distinct prion diseases in these
natural host species.
The pattern and morphology of the pan-CD44
labeling in prion-infected brain indicated an astrocytic
source, as observed previously in Alzheimer’s disease
(Akiyama et al., 1993). Immunostaining of prion disease-affected
brains with an antibody against the common (pan) extracellular
N-terminus of CD44 surrounded, but did not co-localize, with
cytoplasmic and cytoskeletal GFAP. To provide additional
confirmation that the source of the CD44 was astrocytic in
nature we investigated further the expression of splice variant
CD44v6, since independent studies have shown that when this
variant is upregulated in certain cell populations it is coupled
to the cytoskeleton when activated (Tremmel et al., 2009). Our
data suggested that the distribution of splice variant CD44v6
expression was mostly associated with the GFAP+ compartment
of relevant reactive astrocytes following prion infection. In some
strain/host combinations, additional diffuse immunostaining
was also apparent in association with the cell membrane.
Furthermore, the lack of labeling with the N-terminal pan-CD44
antibody in that same GFAP+ compartment implies that the v6
epitope in the extracellular stem region of the CD44 protein is
retained whereas the panCD44 N-terminal epitope is not. Thus
it is plausible that during CNS prion disease intracellular and
potentially activated CD44v6 has been N-terminally cleaved
by extracellular proteases, rather than intracellular γ-secretase
cleavage (Nagano and Saya, 2004; Pelletier et al., 2006; Anderegg
et al., 2009). Data from Alzheimer’s disease patients has also
revealed increases in other CD44 splice variants, in particular
CD44v3 and CD44v10 (Pinner et al., 2017). Whether the
expression of other CD44 splice variants is similarly induced in
astrocytes during prion disease remains to be determined.
Together, our data show that during CNS prion disease
specific reactive astrocytes express high levels of CD44 and the
splice variant form, CD44v6. Analysis of CD44 expression in
distinct regions throughout the brain also suggested that CD44
was not universally upregulated in GFAP+ activated astrocytes.
The precise role of the CD44+ astrocytes during CNS prion
disease remains to be determined. CD44 is a multifunctional
single-chain transmembrane glycoprotein, which mediates
cellular responses to the extracellular environment (Ponta
et al., 2003; Dzwonek and Wilczynski, 2015). Within the
CNS CD44 has been shown to regulate the functional and
structural plasticity and integrity of dendritic spines and
synapses (Skupien et al., 2014; Roszkowska et al., 2016), as
well as regulating astrocyte morphology (Konopka et al.,
2016). Since these features are adversely affected during CNS
prion disease (Jeffrey et al., 1995, 2000) it is plausible that the
altered CD44 expression described here may contribute to the
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development of the neuropathology. Transcriptomic analyses
of the reactive astrocytes induced by various pro-inflammatory
stimuli have shown that CD44 expression is significantly
elevated in neurotoxic A1 astrocytes when compared to A2
astrocytes (Liddelow et al., 2017). Thus is it plausible that
the enhanced expression of CD44 or CD44v6 during CNS
prion disease may also be indicative of a neurotoxic phenotype
in the reactive astrocytes. Specific blockade of the ability of
microglia to stimulate A1 astrocyte conversion can provide
neuroprotection in a mouse model of α-synucleinopathy-induced
neurodegeneration (Yun et al., 2018). Further studies are
required to determine whether the modulation of astrocyte
activation may likewise be beneficial during CNS prion disease.
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